{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:15:05Z","timestamp":1783149305253,"version":"3.54.6"},"reference-count":18,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Sage Open Medical Case Reports"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>A 70-year-old male with type 2 diabetes presented to the emergency department with severe abdominal pain and dyspnea after 24\u2009weeks of treatment with weekly subcutaneous semaglutide (1\u2009mg). He was diagnosed with acute pancreatitis and diabetic ketoacidosis (DKA) and admitted to the intensive care unit. Following 5\u2009days of stabilization and symptom relief, he was transferred to a general ward. However, the patient subsequently developed a high-grade fever persisting for 3\u2009days, accompanied by severe leukocytosis, despite normalized serum lipase levels. A repeat abdominal computed tomography scan revealed acute acalculous cholecystitis complicated by gallbladder rupture. The patient underwent emergency percutaneous transhepatic gallbladder drainage and antibiotic therapy, leading to gradual recovery. This clinical course illustrates a rare cascade of severe complications in a patient receiving a glucagon-like peptide-1 (GLP-1) receptor agonist. Specifically, when new-onset systemic symptoms emerge following the initial stabilization of a critical illness, clinicians should maintain vigilance for repeating imaging studies. This rare case highlights the need for further investigation into whether the pharmacological effects of GLP-1 receptor agonists, such as biliary stasis, might act as a predisposing factor for complex biliary complications in the setting of severe physiological stress.<\/jats:p>","DOI":"10.1177\/2050313x261463142","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:30:36Z","timestamp":1782919836000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Concurrent diabetic ketoacidosis, acute pancreatitis, and subsequent ruptured acalculous cholecystitis in a patient receiving semaglutide: A case report"],"prefix":"10.1177","volume":"14","author":[{"given":"Chuan-Tai","family":"Chiu","sequence":"first","affiliation":[{"name":"Division of Endocrine and Metabolism, Department of Internal Medicine, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, New Taipei City, Taiwan (R.O.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hui","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of Endocrine and Metabolism, Department of Internal Medicine, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, New Taipei City, Taiwan (R.O.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1358-4415","authenticated-orcid":false,"given":"Chia-Hui","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Endocrine and Metabolism, Department of Internal Medicine, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, New Taipei City, Taiwan (R.O.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","unstructured":"Sun H Saeedi P Karuranga S et al. IDF Diabetes Atlas: global regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022; 183: 109119. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018; 27(4): 740\u2013756. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001","DOI":"10.1016\/j.cmet.2018.03.001"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","unstructured":"Marso SP Bain SC Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19): 1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","unstructured":"Husain M Birkenfeld AL Donsmark M et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381(9): 841\u2013851. https:\/\/doi.org\/10.1056\/NEJMoa1901118","DOI":"10.1056\/NEJMoa1901118"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","unstructured":"Smits MM Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne) 2021; 12: 645563. https:\/\/doi.org\/10.3389\/fendo.2021.645563","DOI":"10.3389\/fendo.2021.645563"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","unstructured":"Storgaard H Cold F Gluud LL et al. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab 2017; 19(6): 906\u2013908. https:\/\/doi.org\/10.1111\/dom.12885","DOI":"10.1111\/dom.12885"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","unstructured":"He L Wang J Ping F et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 2022; 182(5): 513\u2013519. https:\/\/doi.org\/10.1001\/jamainternmed.2022.0338","DOI":"10.1001\/jamainternmed.2022.0338"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","unstructured":"Nauck MA Meier JJ Cavender MA et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 2017; 136(9): 849\u2013870. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028136","DOI":"10.1161\/CIRCULATIONAHA.117.028136"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","unstructured":"Yang Z Yu M Mei M et al. The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system. Nutr Metab Cardiovasc Dis 2022; 32(2): 504\u2013510. https:\/\/doi.org\/10.1016\/j.numecd.2021.10.003","DOI":"10.1016\/j.numecd.2021.10.003"},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","unstructured":"Nauck MA Quast DR Wefers J et al. GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art. Mol Metab 2021; 46: 101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102","DOI":"10.1016\/j.molmet.2020.101102"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","unstructured":"Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009; 32 Suppl 2: S151\u2013S156. https:\/\/doi.org\/10.2337\/dc09-S301","DOI":"10.2337\/dc09-S301"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","unstructured":"Ehrmann D Kulzer B Roos T et al. Risk factors and prevention strategies for diabetic ketoacidosis in people with type 2 diabetes. Lancet Diabetes Endocrinol 2020; 8(5): 436\u2013446. https:\/\/doi.org\/10.1016\/S2213-8587(20)30042-5","DOI":"10.1016\/S2213-8587(20)30042-5"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","unstructured":"Nair S Yadav D Pitchumoni CS. Association of diabetic ketoacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA. Am J Gastroenterol 2000; 95(10): 2795\u20132800. https:\/\/doi.org\/10.1111\/j.1572-0241.2000.03188.x","DOI":"10.1111\/j.1572-0241.2000.03188.x"},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","unstructured":"Huffman JL Schenker S. Acute acalculous cholecystitis: a review. Clin Gastroenterol Hepatol 2010; 8(1): 15\u201322. https:\/\/doi.org\/10.1111\/j.1572-0241.2000.03188.x","DOI":"10.1016\/j.cgh.2009.08.034"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","unstructured":"Laurila J Syrj\u00e4l\u00e4 H Laurila PA et al. Acute acalculous cholecystitis in critically ill patients. Acta Anaesthesiol Scand. 2004;48(8):986\u2013991. https:\/\/doi.org\/10.1111\/j.0001-5172.2004.00426.x","DOI":"10.1111\/j.0001-5172.2004.00426.x"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","unstructured":"Parekh S Andrawes S Giordano C et al. Acute perforated acalculous cholecystitis. Appl Radiol 2018; 47(2): 20\u201323. https:\/\/www.appliedradiology.com\/articles\/acute-perforated-acalculous-cholecystitis","DOI":"10.37549\/AR2459"},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","unstructured":"Smits MM Tonneijck L Muskiet MH et al. Biliary effects of liraglutide and sitagliptin a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Diabetes Obes Metab 2016; 18(12): 1217\u20131225. https:\/\/doi.org\/10.1111\/dom.12748","DOI":"10.1111\/dom.12748"},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","unstructured":"Derici H Kara C Bozdag AD et al. Diagnosis and treatment of gallbladder perforation. World J Gastroenterol 2006; 12(48): 7832\u20137836. https:\/\/doi.org\/10.3748\/wjg.v12.i48.7832","DOI":"10.3748\/wjg.v12.i48.7832"}],"container-title":["Sage Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X261463142","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X261463142","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X261463142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:17:16Z","timestamp":1783145836000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X261463142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":18,"alternative-id":["10.1177\/2050313X261463142"],"URL":"https:\/\/doi.org\/10.1177\/2050313x261463142","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"value":"2050-313X","type":"print"},{"value":"2050-313X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"2050313X261463142"}}